Spexis AG (XSWX:SPEX) Other Gross PPE : CHF0.47 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Other Gross PPE?

Spexis AG's Other Gross PPE for the quarter that ended in Dec. 2023 was CHF0.47 Mil.

Spexis AG's quarterly Other Gross PPE increased from Dec. 2022 (CHF0.47 Mil) to Jun. 2023 (CHF1.45 Mil) but then declined from Jun. 2023 (CHF1.45 Mil) to Dec. 2023 (CHF0.47 Mil).

Spexis AG's annual Other Gross PPE declined from Dec. 2021 (CHF1.91 Mil) to Dec. 2022 (CHF0.47 Mil) but then increased from Dec. 2022 (CHF0.47 Mil) to Dec. 2023 (CHF0.47 Mil).

Spexis AG Other Gross PPE Historical Data

The historical data trend for Spexis AG's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG Other Gross PPE Chart

Spexis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

15.27

1.91

0.47

Spexis AG Semi-Annual Data
	Dec13	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Gross PPE	Get a 7-Day Free Trial													1.91	2.12	0.47	1.45	0.47

Spexis AG Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Spexis AG (XSWX:SPEX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

SPEXz:UK

Address

Hegenheimermattweg 125, Allschwil, CHE, CH-4123

Website

https://www.polyphor.com

Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (XSWX:SPEX) Headlines

No Headlines